Incyte Corp. INCY, -1.55% shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,